William Blair Investment Management LLC Purchases 7,317 Shares of PROCEPT BioRobotics Corporation $PRCT

William Blair Investment Management LLC raised its position in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 2.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 328,621 shares of the company’s stock after buying an additional 7,317 shares during the quarter. William Blair Investment Management LLC owned about 0.59% of PROCEPT BioRobotics worth $18,929,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. ANTIPODES PARTNERS Ltd bought a new stake in shares of PROCEPT BioRobotics in the first quarter valued at $30,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of PROCEPT BioRobotics in the first quarter valued at $40,000. CWM LLC raised its stake in shares of PROCEPT BioRobotics by 69.5% in the first quarter. CWM LLC now owns 873 shares of the company’s stock valued at $51,000 after buying an additional 358 shares during the period. Nisa Investment Advisors LLC raised its stake in shares of PROCEPT BioRobotics by 32.5% during the 1st quarter. Nisa Investment Advisors LLC now owns 1,100 shares of the company’s stock valued at $64,000 after purchasing an additional 270 shares during the period. Finally, IFP Advisors Inc raised its stake in shares of PROCEPT BioRobotics by 358.9% during the 1st quarter. IFP Advisors Inc now owns 3,313 shares of the company’s stock valued at $193,000 after purchasing an additional 2,591 shares during the period. 89.46% of the stock is currently owned by institutional investors.

PROCEPT BioRobotics Price Performance

PRCT opened at $32.97 on Monday. The stock has a 50-day moving average price of $37.72 and a 200-day moving average price of $49.50. PROCEPT BioRobotics Corporation has a 12-month low of $32.11 and a 12-month high of $103.81. The company has a current ratio of 9.21, a quick ratio of 7.86 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $1.83 billion, a P/E ratio of -21.27 and a beta of 0.99.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.06. PROCEPT BioRobotics had a negative return on equity of 23.73% and a negative net margin of 30.60%.The firm had revenue of $79.18 million during the quarter, compared to analysts’ expectations of $75.67 million. During the same period in the prior year, the business earned ($0.50) EPS. The company’s revenue for the quarter was up 48.3% compared to the same quarter last year. Equities analysts predict that PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently issued reports on PRCT. Weiss Ratings reiterated a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research note on Wednesday, October 8th. Stephens began coverage on PROCEPT BioRobotics in a research report on Wednesday, July 9th. They set an “overweight” rating and a $70.00 target price for the company. Oppenheimer upgraded PROCEPT BioRobotics from a “market perform” rating to an “outperform” rating and set a $60.00 target price for the company in a research report on Tuesday, September 2nd. Wells Fargo & Company reduced their target price on PROCEPT BioRobotics from $75.00 to $58.00 and set an “overweight” rating for the company in a research report on Thursday, August 7th. Finally, Wall Street Zen upgraded PROCEPT BioRobotics from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Seven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $67.50.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).